Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation.
We have recently described a method for preparing lipid-based DNA particles (LDPs) that form spontaneously when detergent-solubilized cationic lipids are mixed with DNA. LDPs have the potential to be developed as carriers for use in gene therapy. More importantly, the lipid-DNA interactions that give rise to particle formation can be studied to gain a better understanding of factors that govern lipid binding and lipid dissociation. In this study the stability of lipid-DNA interactions was evaluated by measurement of DNA protection (binding of the DNA intercalating dye TO-PRO-1 and sensitivity to DNase I) and membrane destabilization (lipid mixing reactions measured by fluorescence resonance energy transfer techniques) after the addition of anionic liposomes. Lipid-based DNA transfer systems were prepared with pInexCAT v.2.0, a 4.49-kb plasmid expression vector that contains the marker gene for chloramphenicol acetyltransferase (CAT). LDPs were prepared using N-N-dioleoyl-N,N-dimethylammonium chloride (DODAC) and either 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). For comparison, liposome/DNA aggregates (LDAs) were also prepared by using preformed DODAC/DOPE (1:1 mole ratio) and DODAC/DOPC (1:1 mole ratio) liposomes. The addition of anionic liposomes to the lipid-based DNA formulations initiated rapid membrane destabilization as measured by the resonance energy transfer lipid-mixing assay. It is suggested that lipid mixing is a reflection of processes (contact, dehydration, packing defects) that lead to formulation disassembly and DNA release. This destabilization reaction was associated with an increase in DNA sensitivity to DNase I, and anionic membrane-mediated destabilization was not dependent on the incorporation of DOPE. These results are interpreted in terms of factors that regulate the disassembly of lipid-based DNA formulations.
Harvie
P
P
Division of Medical Oncology, Department of Advanced Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada. pharvie@bccancer.bc.ca
Wong
F M
FM
Bally
M B
MB
D000818:Animals; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis; D004247:DNA / Q000737:chemistry* / Q000378:metabolism; D003851:Deoxyribonucleases; D003902:Detergents; D004337:Drug Carriers; D008081:Liposomes / Q000737:chemistry*; D008546:Melanoma, Experimental; D051379:Mice; D008958:Models, Molecular; D008968:Molecular Conformation; D009690:Nucleic Acid Conformation; D010713:Phosphatidylcholines / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry; D010715:Phosphatidylglycerols / Q000737:chemistry; D000644:Quaternary Ammonium Compounds / Q000737:chemistry; D011994:Recombinant Proteins / Q000096:biosynthesis; D012995:Solubility; D013329:Structure-Activity Relationship; D014162:Transfection / Q000379:methods*; D014407:Tumor Cells, Cultured; D014494:Unithiol / Q000737:chemistry
D003902:Detergents; D004337:Drug Carriers; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010715:Phosphatidylglycerols; D000644:Quaternary Ammonium Compounds; D011994:Recombinant Proteins; C015831:dimethyldioctadecylammonium; D014494:Unithiol; C042077:N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)phosphatidylethanolamine; C020888:1,2-dielaidoylphosphatidylethanolamine; D004247:DNA; C002773:dimyristoylphosphatidylglycerol; D015500:Chloramphenicol O-Acetyltransferase; D003851:Deoxyribonucleases; C017251:1,2-oleoylphosphatidylcholine